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Abstract
Purpose Increasing numbers of atypical femoral fractures
have been reported among long-term bisphosphonate users.
We evaluated clinical characteristics of atypical femoral frac-
tures throughout Korean multicenter studies.
Methods We retrospectively analysed the bone mineral den-
sity, prodromal symptoms before femoral fracture, and
medication history of osteoporosis in 76 cases of atypical
femoral fracture.
Results The mean age of cases was 71.4±8.8 (range, 43–89)
years old. The mean follow-up period after the fracture opera-
tion was 24.5±12.9 (range, 12–79)months. BMIwas 23.2±3.0
on average. The mean BMD of femur was −1.9±1.4 (range,
−4.8 to 1.3). Prodromal symptoms including thigh pain before
femoral fracture appeared in 22 (28.9 %) of 76 patients. All
patients included in the study used bisphosphonate. The dura-
tion of taking bisphosphonate before fracture was 36.8±50.8
(one–204 months) months. Fifty-seven (75 %) of 76 patients
were taking the medication for more than three years. Delayed
union occurred in 43 (56.5 %) of 76 patients. Delayed union
was defined as a fractured bone that did not completely heal
within six months of injury. The group of having taken anti-
osteoporotic medication for more than three years showed
relatively longer union period compared to that for a shorter
period medication group (4.8±2.5 months vs 9.3±3.7 months,
p=0.017). The delayed union developed in 43 (56.5 %) of 76
patients and showed a significantly higher incidence in the
group with long-term therapy (five/43 vs 38/43, p=0.021).
The bilateral femoral fractures developed in 23 (30.2 %) of
76 patients and showed a high incidence in the group medicat-
ed more than three years (two/23 vs 21/23, p=0.039).
Conclusions The longer bisphosphonates are used, the more
the cases of delayed union and the more frequent the devel-
opment of bilateral fractures following unilateral fractures.
With regard to the delayed union, the methods of the acceler-
ation of fracture healing may be beneficial in atypical femoral
fracture patients who had been receiving long-term
bisphosphonates therapy. Careful observation is required for
contra-lateral femurs due to a high incidence of bilateral
atypical femoral fractures.
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Introduction
Osteoporosis is associated with significant morbidity and
mortality [1, 2], and approximately 50% of women older than
50 years will sustain an osteoporosis-related fracture during
their lifetime, and one of five patients with an osteoporosis-
related fracture will die within 12 months [3–5].
Bisphosphonates (BPs) reduce the overall risk of fractures
among patients with osteoporosis, with a long-lasting benefi-
cial effect [6], but it is known that they reduce bone remodel-
ing, they might “freeze” the skeleton, and they allow accumu-
lation of micro-cracks over time, leading to fatigue fractures
(also called stress fractures) [7].
In published case reports that classified femoral fractures as
stress fractures or non-stress fractures according to their ra-
diographic appearance, among patients admitted to tertiary
centres, such stress fractures (commonly called atypical fem-
oral fractures, the term used here) were more common in
patients who received bisphosphonate than in those who did
not [8]. However, recent data suggests that the relative risk of
pat ients wi th a typica l femoral f rac tures taking
bisphosphonates is high, but the absolute risk of atypical
femoral fracture associated with bisphosphonates therapy is
low [9–11]. Several studies suggest that the incidence of
atypical femoral fractures increases with increasing duration
of exposure [12].
The relationships between the duration of bisphosphonates
use and atypical femoral fractures have not been studied
thoroughly until recently and most studies have been limited
to Westerners and females. There have been few documented
multicenter studies of atypical femoral fractures in Korea
compared with the number of studies that have been conduct-
ed in Western populations.
The aim of this multicenter study was to investigate the
clinical features of atypical femoral fractures among
bisphosphonates users, to clarify the association between
long-term (greater than three year) bisphosphonates therapy
and characteristics of atypical femoral fractures.
Methods
Patients and clinical data collection
The Institutional Review Boards of the participating centres
provided ethical approval of the study.
A total of 108 consecutive patients with displaced atyp-
ical femoral fracture sustained after minimal trauma be-
tween January 2005 and June 2011 were retrospectively
reviewed based on images and the medical records from eight
tertiary referral hospitals. According to the criteria of the
ASBMR Task Force 2013, atypical femoral fracture was
defined as a fracture located along the femur from just distal
to the lesser trochanter to just proximal to the supracondylar
flare, associated with minimal or no trauma history, transverse
or short oblique configuration, non-comminuted or minimal
comminuted, complete fractures extending through both cor-
tices or incomplete fracture involving only the lateral cortex,
localized periosteal or endosteal thickening of the lateral
cortex [11].
Radiographs of all patients were assessed by two orthopae-
dic surgeons in each participating centre, blinded for all back-
ground information.
Among these patients, 32 were excluded because of history
of pathologic fracture, high energy traumas, deformities, a
previous history of femoral operation on another site, or
insufficient data. We included the patients with a history of
cancer which were not related to the femur fracture, but
excluded pathologic fracture as mentioned. Finally, 76 pa-
tients were included for the analyses (Fig. 1).
Data collected from the medical record included detailed
demographic and clinical data such as hypertension, diabetes,
renal disease, cancers, steroid use, and hormonal treatment in
female patients. The use of bisphosphonates and its duration,
the history of prodromal symptoms, and the mechanisms of
injury were recorded. The history of operation was also gath-
ered from medical records including types of the operations
and instruments used.
On radiologic evaluation, we classified fracture pattern
(subtrochanteric or femur shaft fractures) using radiologic
analyses. The subtrochanteric fracture was defined as ex-
tending 5 cm below the lesser trochanter. The femur shaft
fracture was defined as extending from below the
subtrochanteric region to supracondylar metaphyseal flare.
We also checked bilaterality for atypical femoral fractures
on initial and follow-up radiographs. Bony union of the
atypical femoral fracture was assessed using plain radio-
graphs at three months, six months, 12 months, and yearly
thereafter, but a shorter interval of check up was made
when a bony union was not seen or controversial. Radio-
graphic healing was defined as bony bridging of three of
four cortices on anteroposterior (AP) and lateral radiographs,
as well as painless weight bearing on the affected extremity.
Dual energy X-ray absorptiometry hip images were taken in
all patients within three months after fractures and thereafter
with an interval of one year at the corresponding hospitals
(Figs. 2, 3, 4, and 5).
Statistical analysis
Baseline data demonstrated means ± standard deviations with
ranges for continuous variables and counts and percentages
for categorical variables. Wilcoxon rank sum test was used for
the comparisons of continuous variables of two groups and
Fisher’s exact test was used for the comparisons of categorical
variables according to the different variables. All statistical
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analyses were carried out using SPSS version 20.0 software
package (Chicago, IL, USA). P -values less than 0.05 were
considered statistically significant. This study was reviewed
and approved by the institutional review board, and informed
consent from the patients was waived.
Fig. 1 Flow diagram of the
selection of the patients
Fig. 2 Pre-operative radiography of an 80-year-old woman who had
taken oral alendronate medication for five years prior to atypical femoral
subtrochantric fracture Fig. 3 Immediate postoperative radiography
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Results
The mean age of the 76 patients was 71.4±8.8 years. The
majority of patients were females (three males and 73 fe-
males). The BMI was 23.2±3.0 kg/m2 on average. The bone
mineral density (BMD) of total femurs was −1.9±1.4. Forty
eight (63.7 %) of 76 patients were in the osteopenic range, not
osteoporotic range.
Seven (9.2 %) of 76 patients had renal diseases and nine
(11.8 %) of 76 patients had a history of steroids use. Five
(6.6 %) of 76 patients had a history of cancers and 26 (34.2 %)
of 76 patients underwent hormone replacement treatments
(Table 1).
All patients included in the study took bisphosphonates. The
total duration of taking anti-osteoporotic medications was 36.8
±50.8 months, and 57 (75%) of 76 patients took them for more
than three years. With regard to the anti-osteoporotic medica-
tions, alendronate was administered to 41 (53.9 %) patients,
risedronate to 18 (23.6 %) patients, ibandronate to ten (13.1 %),
pamidronate to one (1.3 %), zolendronate to one (1.3 %), and
two or more of these to five (6.5 %) patients (Table 2).
Prodromal symptoms developed in 22 (28.9 %) of the 76
patients and the duration of the symptoms was 6.3±8.1 months.
With respect to the types of fractures, 59 (77.6 %) patients
showed subtrochanteric fractures, and in 17 (22.4 %) patients
femoral shafts were involved. Regarding themethods of surgical
treatments, 37 (62.7 %) patients of subtrochanteric fractures and
nine (52.9 %) of femoral shaft fractures were treated by open
reductions, which exceeded the number of closed reductions.
The duration of union was 9.4±5.9 months and the union
was delayed for more than six months in 43 (56.5 %) patients.
Fig. 4 At six months after operation, delayed union of fracture was
noticed. Parathyroid hormone (PTH) was administered subcutaneously
for four months
Fig. 5 Union of fracture was obtained 11 months after operation
Table 1 Demographic data of the patients
Variable Atypical fracture (n=76)
Age (year) 71.4±8.8 (range, 43–89)
Gender (male : female) 3 (3.94 %)/73 (96 %)
BMI 23.2±3.0
BMD (T-score, femur) −1.9±1.4 (range, −4.8 to −1.3)
F/U after operation (months) 24.5±12.9 (range, 12–79)
Renal disease (n) 7 (9.2 %)
Steroid use (n) 9 (11.8 %)
Hormone replacement therapy (n) 26 (34.2 %)
Cancer history (n) 5 (6.6 %)
BMI body mass index, BMD bone mineral density, F/U follow up
Table 2 Characteristics of the anti-osteoporotic medications
Characteristic Patients (n=76)
Medication duration (months) 36.8±50.8 months (range, 1–204)
>3 year medication (n) 57 (75 %)
Alendronate (n) 41 (53.9 %)
Risendronate (n) 18 (23.6 %)
Ibandronate (n) 10 (13.1 %)
Pamidronate (n) 1 (1.3 %)
Zolendronate (n) 1 (1.3 %)
Mixed (n) 5 (6.5 %)
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The majority of patients suffered from unilateral fractures,
and bilateral fractures occurred in 23 (30.2 %) patients. The
interval between the fractures on one side and the other was
two years on average (23.3±26.2 months) (Table 3).
Considering the duration of union of fractures and the
development of bilateral fractures according to the duration
of taking anti-osteoporotic medications, the duration of union
was prolonged with the administration of medications for
more than three years. The duration of union was 4.8±
2.5 months in patients who had taken medications for less
than three years, and 9.3±3.7 months in those who had been
medicated for more than three years. This difference was
statistically significant with a P value of 0.017. Five out of
19 patients (26.3 %) represented delayed union within
three years of medication while 38 out of 57 patients
(66.6 %) developed delayed union with more than
three years of medication. This difference was also statistically
significant (P=0.021).
Two out of 19 patients (10.5%) developed bilateral fractures
with less than three years of medication while 21 out of 57
patients (36.8 %) experienced bilateral fracture with more than
three years of medication. The incidence of bilateral fractures in
the more-than-three-year-medication group was higher than the
less-than-three-year-medication group, with the difference be-
ing statistically significant (P=0.039) (Table 4).
Discussion
We attempted to demonstrate the relationship between the
administration of anti-osteoporotic medications and atypical
femoral fractures, by analysing the cases diagnosed as having
atypical fractures among the patients who were taking
bisphosphonates, and reviewing the results of Korean multi-
center studies. We also tried to elucidate the inter-relationship
between the atypical fractures and the long-term administration
of anti-osteoporotic medications for more than three years.
An interesting finding of our study was the discovery that
the mean bone density T-scores of femur at time of fracture
were in the osteopenic range. Forty eight (63.7 %) of 76
patients had osteopenia or normal BMD. The majority of the
patients did not have osteoporosis. This finding was similar
with recent reports, and supports that atypical femoral frac-
tures are a separate fracture entity with osteoporotic femur
fracture. As shown in our cases, prolonged suppression of
bone remodeling improves BMD, but made bone less able
to deform, therefore predisposing to accumulation of
microdamage. These findings suggest that bisphophonate
therapy could be stopped when BMD is increased, in order
to prevent adverse events, in agreement with other authors
which recommend a drug holiday in selected patients [13].
In our study, delayed unions following the treatment of
atypical fractures comprised more than half of cases (56.5 %),
which showed higher percentage than the previous study [14].
Those of Asian race have differences in femur geometry that
may contribute to the high prevalence of delayed union.
Regarding the bilaterality of atypical femur fracture, fractures
developed in 23 out of 76 patients (30.2 %). The high inci-
dence of bilaterality is consistent with previous reports [14].
These two variables (union being delayed for more than
six months, and bilateral fractures) had statically significant
relationships with the duration of taking medications. The
longer the duration of taking medications, the more frequent
the incidence of these variables.
Table 3 Characteristics of the
clinical symptoms and fractures Characteristic Atypical fracture (n=76)
Prodromal symptom (n) 22 (28.9 %)
Prodromal symptom duration (months) 6.3±8.1 months (range, 1–37)
Fracture type Subtrochanteric (n) 59 (77.6 %)
Shaft (n) 17 (22.4 %)
Open reduction Subtrochanteric (n=59) 37 (62.7 %)
Shaft (n=17) 9 (52.9 %)
Duration of union (months) 9.4±5.9 months (range, 4–26)
Delayed union (>6 months) (n) 43 (56.5 %)
Bilateral fracture (n) Incidence (n) 23 (30.2 %)
Interval between fracture 23.3±26.2 months (range, 5–84)
Table 4 Differences of charac-
teristics of the fractures according
to the duration of bisphosphonate
therapy
Characteristic <3 year medication (n=19) >3 year medication (n=57) p-value
Duration of union (months) 4.8±2.5 months 9.3±3.7 months 0.017
Delayed union (n=43) 5 38 0.021
Bilateral fraction (n=23) 2 21 0.039
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Delayed union of femur fracture may lead to long-term
recumbent status and poor functional outcomes. Delayed frac-
ture healing may indicate a need for more aggressive medical
and biologic augmentations.
The bone graft is known as the gold standard of treatment
of delayed union, and studies on the use of parathyroid hor-
mone (PTH) in delayed union have resulted in an improve-
ment in the union.
The use of PTH is approved for use in patients who are at
high risk for osteoporotic fractures. With its short half life,
intermittent daily administration has been shown to increase
bone mass by proliferating the osteoblast and suppressing the
apoptosis of osteoblast [15]. Bukata et al., who presented an
observational cohort of 145 patients with delayed fracture
healing, noted that 135 patients (93 %) achieved radiological
union of fracture with PTH administration within 2.8 months
[16]. Recently, Aspenberg et al. showed that osteoporotic
distal radius fractures that were treated with PTH resulted in
earlier cortical bridging compared to a placebo group [17].
The possibility of inducing fracture healing through physical
methods has been investigated. Recent studies have shown an
accelerating effect of low-intensity pulsed ultrasound (LIPUS)
on delayed union. Rubin et al. reported that The Food and Drug
Administration approved the use of low-intensity ultrasound
for the accelerated healing of delayed union [18]. Jingushi et al.
analysed the factors that influence the union rate on delayed
union and nonunion. They concluded that the earlier LIPUS
treatments were started, the better the results [19].
In this study, 43 (56.5 %) of 76 patients need more than
six months for fracture healing. We think that bisphosphonate-
related femoral fractures require additional methods for stimu-
lating bone healing. Thus, using PTH medications and LIPUS
treatment in the postoperative period may be helpful to prevent
delayed union of bisphosphonate-associated atypical fracture.
Another finding is the high occurrence of bilateral femoral
fractures. In this study, 23 (30.2 %) of 76 patients experienced
bilateral fracture. Notedly, 21 (91.3 %) patients belonged to
the long-term (greater than three year) medication group.
Regarding bilateral atypical femoral fracture, few publications
described treatments and outcomes.
Das et al. [20] performed a retrospective review of
alendronate-associated subtrochanteric fractures that tend to
be bilateral, have unique radiological features, are associated
radiologically with a pre-existing ellipsoid thickening of the
lateral femoral cortex and are likely to be preceded by prodro-
mal pains. Ha et al. [21] reported femoral insufficiency frac-
tures after long-term bisphosphonate therapy seldom healed
spontaneously and most patients had surgery due to displace-
ment of fractures and persistent pain. Capeci and Tejwani
reported seven patients who sustained bilateral subtrochanteric
or diaphyseal femoral fracture. They recommended that pro-
phylactic fixation should be considered for contralateral femur
stress fractures [22].
In this study, we found that long-term bisphosphonate
therapy was associated with a high incidence of bilateral
fracture. Thus, routine radiographs of the contra-lateral femurs
and more frequent follow-up visits are necessary, especially if
a patient has a medical history of long-term bisphosphonate
therapy. If a contralateral stress fracture is found, prophylactic
fixation should be considered.
Limitations of this study could be the fact that it is retro-
spectively undertaken and that the collection of data is based on
medical records which may pose the possibility of inaccuracy.
Conclusions
In our study, the longer bisphosphonates are used, the more
the cases of delayed union and the more frequent the devel-
opment of bilateral fractures following unilateral fractures. We
believe that more aggressive medical and surgical strategies
are necessary for patients on long-term bisphosphonate ther-
apy who present with atypical femoral fracture. Considering
high incidence of bilateral atypical femoral fracture, careful
observation is required for the contralateral femur.
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